Development to Improve VERIGRAFT´s Tissue Personalization Bioreactor GMP Process
| Reference number | |
| Coordinator | VeriGraft AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2024 - October 2025 |
| Status | Ongoing |
| Venture | Utlysning Infrastruktur for the development of accurate drug treatment |
| Call | Use infrastructures to develop precision medicine |
Purpose and goal
The purpose of the project is to further develop VERIGRAFT´s bioreactor and manufacturing process so that the process becomes completely closed and thus safer and less complex to implement. The improvements will significantly increase the efficiency of the tissue therapy manufacturing process and are expected to reduce costs by reducing requirements on GMP facilities as well as staff time spent on the process.
Expected effects and result
The intended improvements will streamline and enable cost-effective manufacturing of customized tissue therapies for larger clinical studies and for subsequent commercialization. In the long run, reduced manufacturing costs are expected to contribute to a wider application of VERIGRAFT´s individualized advanced therapies.
Planned approach and implementation
VERIGRAFT and CCRM Nordic will have a close collaboration through the organizations´ facilities and personnel as well as their competence and experience. CCRM Nordic offers extensive bioprocessing and process development expertise within its scientific teams, supported by new labs equipped with advanced development, manufacturing, and analytical tools.